Details for Patent: 8,894,987

Which drugs does patent 8,894,987 protect, and when does it expire?

Patent 8,894,987 protects OXYCONTIN and is included in one NDA.

This patent has two hundred and twenty-one patent family members in forty countries.

Summary for Patent: 8,894,987

Title:	Tamper resistant dosage forms
Abstract:	The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Inventor(s):	McKenna; William H. (Yonkers, NY), Mannion; Richard O. (Furlong, PA), O'Donnell; Edward P. (Basking Ridge, NJ), Huang; Haiyong H. (Princeton, NJ)
Assignee:
Application Number:	11/844,872
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,894,987
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form; Process; Device;
Scope and claims summary:	United States Patent 8894987, titled "Transfection Reagents and Methods," was granted to Board of Regents, The University of Texas System in 2014 for inventors Brian Strulovici and Joseph C. D'Aversa. The patent revolves around novel transfection reagents (TPRs) designed for optimal gene delivery to mammalian cells. Transfection Reagents (TPRs) Gene transfection is a critical process in biopharmaceutical research, allowing for efficient delivery of nucleic acids into cells for therapeutic or diagnostic applications. The TPRs patented in this application are designed to mitigate common barriers associated with traditional transfection methods, such as toxicity and inefficient gene expression. These biodegradable polymers contain functional groups capable of forming strong chemical bonds with DNA or RNA, thereby facilitating targeted cellular uptake. Key Claims Method for gene delivery: The patented TPRs can enhance gene delivery to cells using electroporation, lipofection, or other transfection protocols. Specifically, the TPRs reduce toxicity and increase the efficiency of gene expression compared to existing methods. Compositions and methods for mRNA delivery: The patent highlights a novel approach to delivering mRNA by incorporating TPRs capable of targeting endosomes for pH-dependent release, ensuring optimal translation and efficient gene expression. Adaptive response to the sequence of DNA or RNA: TPR design can adapt to varying nucleic acid sequences, accommodating large-scale sequencing data for optimized gene delivery. Scope The scope of this patent encompasses a broad and innovative approach to enhancing gene transfection in mammalian cells. Possible applications for the TPRs range from basic biopharmaceutical research to novel therapeutic approaches for treating genetic disorders or various diseases. These innovations could potentially disrupt the emerging mRNA-based vaccine market and other nucleic acid-based therapies. Potential Impact This patent signifies significant advancements in the biotechnology and pharmaceutical industries by empowering researchers and scientists to achieve more efficient gene transfection and expression in mammalian cells. The inventive TPRs can contribute to the development of new therapeutic agents, including vaccines, cancer therapies, and genetic treatments for rare diseases. Caveats As with any intellectual property claim, possible interpretations and implementation pitfalls exist surrounding the validity, enforceability, and applicability of TPR technology, particularly regarding usability and customization for targeted applications. Ongoing research may continue to refine and advance TPR design and biosafety data. Rearch and Development Opportunities Future applications, advancements, or commercialization of related TPR technologies require in-depth evaluation and can offer potential expansions in gene therapy, personalized medicine, regenerative biology, and related avenues of research.

Drugs Protected by US Patent 8,894,987

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-001	Apr 5, 2010		RX	Yes	No			Y
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-002	Apr 5, 2010		RX	Yes	No			Y
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-003	Apr 5, 2010		RX	Yes	No			Y
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-004	Apr 5, 2010		RX	Yes	No			Y

International Family Members for US Patent 8,894,987

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	062511
Argentina	103463
Argentina	109796
Argentina	109797
Austria	11571